Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6713471 | 0.91 | RXFP1 (0.33) | RXFP1KMT2AMAPT | |
| SCHEMBL6708749 | 0.89 | SCN9A (0.33) | MAPT | |
| SCHEMBL6712022 | 0.86 | TRPV1 (0.39) | HIF1ANPSR1RXFP1KMT2AMAPT | |
| SCHEMBL6711758 | 0.85 | GRIK1 (0.39) | HIF1ANPSR1RXFP1BACE1 | |
| SCHEMBL6710196 | 0.84 | HIF1A (0.35) | HIF1ANPSR1RXFP1KMT2AGPR35 | |
| SCHEMBL6710199 | 0.84 | HIF1A (0.35) | HIF1ANPSR1RXFP1KMT2AGPR35 | |
| SCHEMBL6711867 | 0.84 | HIF1A (0.37) | HIF1ANPSR1RXFP1KMT2AGPR35 | |
| SCHEMBL6710547 | 0.83 | GRM4 (0.41) | HIF1ANPSR1RXFP1KMT2AMAPT | |
| SCHEMBL6708968 | 0.82 | HIF1A (0.41) | HIF1ANPSR1RXFP1KMT2AGPR35 | |
| SCHEMBL6711730 | 0.82 | HIF1A (0.32) | HIF1ANPSR1RXFP1GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | HIF1A 296/4885NPSR1 2999/4885RXFP1 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.